ClinicalTrials.gg

Program

Elecoglipron Test formulation 1 Dose A

Also written as “Elecoglipron Test formulation 1 Dose B”, “Elecoglipron Test formulation 2 Dose A” and “Elecoglipron Test formulation 2 Dose B”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by AstraZeneca.

Furthest: phase 1, since Jul 20, 20261 company-led study, 1 open or runningNext primary completion: Nov 18, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 1since Jul 20, 2026Jul 20, 2026Nov 18, 2026phase 1 · NCT07723833

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 20, 2026First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT07723833 · 152 planned · United States

Ahead

  1. Nov 18, 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07723833

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07723833Diabetes Mellitus, Type 2 · United States1RecruitingNov 18, 2026152

How it is read

Names in the registry

  • “Elecoglipron Test formulation 1 Dose A”, 1 entry
  • “Elecoglipron Test formulation 1 Dose B”, 1 entry
  • “Elecoglipron Test formulation 2 Dose A”, 1 entry
  • “Elecoglipron Test formulation 2 Dose B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.